Cargando…

Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study

Background: Drug resistant-tuberculosis (DR-TB) patients are provided universal drug susceptibility testing (UDST), anti-TB drugs for the treatment of DR-TB, nutritional support (Nikshay Poshan Yojana - the financial incentive of rupees five hundred per month for each notified DR-TB patient for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Giri, Om P, Kumar, Abhay, Giri, Vishal P, Nikhil, Nishant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982631/
https://www.ncbi.nlm.nih.gov/pubmed/35399462
http://dx.doi.org/10.7759/cureus.22886
_version_ 1784681844123369472
author Giri, Om P
Kumar, Abhay
Giri, Vishal P
Nikhil, Nishant
author_facet Giri, Om P
Kumar, Abhay
Giri, Vishal P
Nikhil, Nishant
author_sort Giri, Om P
collection PubMed
description Background: Drug resistant-tuberculosis (DR-TB) patients are provided universal drug susceptibility testing (UDST), anti-TB drugs for the treatment of DR-TB, nutritional support (Nikshay Poshan Yojana - the financial incentive of rupees five hundred per month for each notified DR-TB patient for the duration for which the patient is on anti-TB drugs) by the Government of India. Methods: This retrospective cohort record-based study was conducted in DR-TB patients. Some 1095 DR-TB patients who have initiated treatment at Nodal DR-TB Centre, Darbhanga Medical College and Hospital (DMCH), Darbhanga, and continued their anti-TB drugs at home blocks were followed till their treatment outcome was known. Data were analyzed by statistical experts of DMCH. Results: Treatment supporters comprised 688 (62.83%) females and 407 (37.17%) males. Different types of treatment supporters noted were accredited social health activists (ASHAs) 622 (56.80%), family members 365 (33.33%), and community health workers 108 (09.86%). Treatment outcome as transfer out was observed in 08 (1.29%), 10 (2.74%), and 13 (12.03%) cases among ASHAs, family members, and community health workers, respectively [statistically significant (p < 0.0001)]. Conclusion: ASHAs proved to be the best treatment supporters in comparison to both family members and community health workers for multi-drug resistant TB (MDR/RR-TB) patients.
format Online
Article
Text
id pubmed-8982631
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89826312022-04-07 Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study Giri, Om P Kumar, Abhay Giri, Vishal P Nikhil, Nishant Cureus Pulmonology Background: Drug resistant-tuberculosis (DR-TB) patients are provided universal drug susceptibility testing (UDST), anti-TB drugs for the treatment of DR-TB, nutritional support (Nikshay Poshan Yojana - the financial incentive of rupees five hundred per month for each notified DR-TB patient for the duration for which the patient is on anti-TB drugs) by the Government of India. Methods: This retrospective cohort record-based study was conducted in DR-TB patients. Some 1095 DR-TB patients who have initiated treatment at Nodal DR-TB Centre, Darbhanga Medical College and Hospital (DMCH), Darbhanga, and continued their anti-TB drugs at home blocks were followed till their treatment outcome was known. Data were analyzed by statistical experts of DMCH. Results: Treatment supporters comprised 688 (62.83%) females and 407 (37.17%) males. Different types of treatment supporters noted were accredited social health activists (ASHAs) 622 (56.80%), family members 365 (33.33%), and community health workers 108 (09.86%). Treatment outcome as transfer out was observed in 08 (1.29%), 10 (2.74%), and 13 (12.03%) cases among ASHAs, family members, and community health workers, respectively [statistically significant (p < 0.0001)]. Conclusion: ASHAs proved to be the best treatment supporters in comparison to both family members and community health workers for multi-drug resistant TB (MDR/RR-TB) patients. Cureus 2022-03-06 /pmc/articles/PMC8982631/ /pubmed/35399462 http://dx.doi.org/10.7759/cureus.22886 Text en Copyright © 2022, Giri et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Pulmonology
Giri, Om P
Kumar, Abhay
Giri, Vishal P
Nikhil, Nishant
Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title_full Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title_fullStr Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title_full_unstemmed Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title_short Impact of Treatment Supporters on the Treatment Outcomes of Drug Resistant-Tuberculosis (DR-TB) Patients: A Retrospective Cohort Study
title_sort impact of treatment supporters on the treatment outcomes of drug resistant-tuberculosis (dr-tb) patients: a retrospective cohort study
topic Pulmonology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8982631/
https://www.ncbi.nlm.nih.gov/pubmed/35399462
http://dx.doi.org/10.7759/cureus.22886
work_keys_str_mv AT giriomp impactoftreatmentsupportersonthetreatmentoutcomesofdrugresistanttuberculosisdrtbpatientsaretrospectivecohortstudy
AT kumarabhay impactoftreatmentsupportersonthetreatmentoutcomesofdrugresistanttuberculosisdrtbpatientsaretrospectivecohortstudy
AT girivishalp impactoftreatmentsupportersonthetreatmentoutcomesofdrugresistanttuberculosisdrtbpatientsaretrospectivecohortstudy
AT nikhilnishant impactoftreatmentsupportersonthetreatmentoutcomesofdrugresistanttuberculosisdrtbpatientsaretrospectivecohortstudy